Status: Not yet recruiting
Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer
This is a small Phase II study testing whether targeted internal radiation treatment (HDREBT) followed by two doses of the immunotherapy drug Nivolumab is safe, practical, and potentially effective before patients undergo surgery (TME) to remove rectal cancer.
Participants needed: 10
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Dr. Te VuongUpdated: Jun 12, 2026Locations: 1
Eligibility criteria
Age ≥18 years at the time of consent. [+22]
Prior anticancer therapy for rectal cancer. [+12]